Andrew Zikic

Andrew Zikic

Auto-generated profile, based on publicly available information

Andrew Zikic

Division of Respiratory Medicine, Department of Pediatrics, The Hospital for Sick Children, Toronto, Canada

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2022 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
AZAndrew Zikic
Andrew Zikic
FRFelix Ratjen
Felix Ratjen
MSMichelle Shaw
Michelle Shaw
ETElizabeth Tullis
Elizabeth Tullis
VWValerie Waters
Valerie Waters

24 March 2026 in Journal of Cystic Fibrosis
Verified
Journal Article
Open access
ESElias Seidl
Elias Seidl
AZAndrew Zikic
Andrew Zikic
SMSrdjan Micic
Srdjan Micic
RVRianne de Vries
Rianne de Vries
JAJulie Avolio
Julie Avolio
HGHartmut Grasemann
Hartmut Grasemann
Breath profile analysis of volatile organic compounds (VOCs) by electronic nose (eNose) technology can distinguish between healthy individuals and people with cystic fibrosis (pwCF). It remains, however, unclear whether CFTR modulator therapy, that corrects the underlying defect in treated pwCF, alters the exhaled breath profiles. In this prospective longitudinal study, eNose-derived exhaled breath profiles were obtained using the SpiroNose® (Breathomix, Leiden, The Netherlands) from 61 CF children before starting therapy with elexacaftor/tezacaftor/ivacaftor (ETI), and at follow-up visits less than 3 and more than 6 months after ETI initiation. Routine clinical outcomes and airway microbiology were assessed at all visits. Twenty-six healthy controls provided single measurements. Longitudinal SpiroNose sensor data were analyzed using linear mixed-effects models and permutational multivariate analysis of variance (PERMANOVA), and exploratory mixed-effects models to test for associations with Staphylococcus aureus (SA) airway infection and clearance. ETI led to improved sweat chloride concentrations, pulmonary function (ppFEV1) and BMI, but no significant changes in SpiroNose sensor signals were observed during follow-up. SpiroNose sensor signals reliably discriminated healthy controls from CF children at baseline and at follow-up on ETI, with consistent differences in multiple SpiroNose sensors. SA airway infection was captured (sensor S7), whereas SA clearance did not result in measurable changes in SpiroNose signals. CFTR modulator therapy with ETI does not significantly alter eNose-derived VOC breath profiles in children with CF. The ability of the eNose to distinguish CF from healthy controls remains unchanged after ETI initiation.

27 March 2024 in The Journal of Pediatrics
Verified
Journal Article
Closed access
AZAndrew Zikic
Andrew Zikic
FKFiona Kritzinger
Fiona Kritzinger
OHOsami Honjo
Osami Honjo
DGDvir Gatt
Dvir Gatt